HSIC

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Henry Schein Inc.

Henry Schein, Inc. is a solutions company for health care professionals powered by a network of people and technology. With more than 19,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Its Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional healthcare clinics, as well as other alternate care sites. Henry Schein operates through a centralized and automated distribution network, with a selection of more than 120,000 branded products and Henry Schein private-brand products in stock, as well as more than 180,000 additional products available as special-order items. A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 31 countries. The Company's sales from continuing operations reached $10.0 billion in 2019, and have grown at a compound annual rate of approximately 13 percent since Henry Schein became a public company in 1995.
CEO
Stanley Bergman
Employees
19000
Headquarters

135 Duryea Rd
Melville, New York 11747-3834
Phone: 16318435500
www.henryschein.com

News

Henry Schein’s Practice Pink Program Continues to Support the Campaign Against Cancer in 2023
Oct 04, 2023 10:31am

Henry Schein, Inc. (Nasdaq: HSIC) today announced the annual launch of its Practice Pink program, an initiative that has raised more than $1.9 million in the past 17 years to support nonprofit organizations dedicated to cancer research and prevention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231003522488/en/ (Graphic:


Source:Wallstreet:Online
Unveiling Henry Schein (HSIC)''s Value: Is It Really Priced Right? A Comprehensive Guide
Sep 27, 2023 16:34pm

Unveiling Henry Schein (HSIC)''s Value: Is It Really Priced Right? A Comprehensive Guide


Source:GuruFocus
Henry Schein Opens Customer Assistance Hotline in Response to Hurricane Idalia | HSIC Stock News
Aug 29, 2023 23:50pm

Henry Schein, Inc. reminds its customers in Florida and all areas in the projected path of Hurricane Idalia that the Henry


Source:Stock Titan
Henry Schein Opens Customer Assistance Hotline in Response to Hurricane Idalia
Aug 29, 2023 22:50pm

Henry Schein, Inc. (Nasdaq: HSIC) reminds its customers in Florida and all areas in the projected path of Hurricane Idalia that the Henry Schein Customer Assistance Hotline is open for dentists and physicians who may experience operational, logistical, or financial issues as a result of damage caused by the hurricane. The toll-free number for all Henry Schein customers is 800-999-9729. The hotline


Source:Wallstreet:Online
Zentek Ltd.: Zentek Announces Distribution and Supply Agreement with Henry Schein, Inc.
Aug 24, 2023 11:26am

GUELPH, ON / ACCESSWIRE / August 24, 2023 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSX-V:ZEN), a graphene technology development and commercialization company has signed a Distributi…


Source:Finanz Nachrichten
Henry Schein Opens Customer Assistance Hotline in Response to Hawaii Wildfires
Aug 10, 2023 18:00pm

Henry Schein, Inc. (Nasdaq: HSIC) reminds its customers in Hawaii that the Henry Schein Customer Assistance Hotline is open for dentists and physicians who may experience operational, logistical, or financial issues as a result of damage caused by the recent wildfires. The toll-free number for all Henry Schein customers is 800-999-9729. The hotline is open 24/7, with real-time assistance available


Source:Wallstreet:Online
Baird maintains Henry Schein at ''neutral'' with a price target of $82.00
Aug 08, 2023 10:22am

https://www.investing.com/news/pro/henry-schein-receives-investment-bank-analyst-rating-update-3147852


Source:Investing.com
Market Volatility Falls Sharply, S&P 500 Snaps 4-Session Losing Streak
Aug 08, 2023 09:56am

The S&P 500 settled higher on Monday, snapping a four-session losing streak. U.S. stocks have notched sharp gains this year, with the benchmark S&P 500 adding around 17.7% in 2023. As far as the earnings season is concerned, 422 S&P 500 companies have released quarterly results as of Friday, with around 79.1% of those exceeding market estimates. Henry Schein Inc (NASDAQ: HSIC ) reported better-than-expected second-quarter earnings. Sage Therapeutics Inc (NASDAQ: SAGE ) shares dipped around … Full story available on Benzinga.com


Source:Benzinga
Henry Schein, Inc. (HSIC) Q2 2023 Earnings Call Transcript
Aug 07, 2023 20:08pm

Henry Schein, Inc. (NASDAQ:NASDAQ:HSIC) Q2 2023 Earnings Conference Call August 7, 2023 10:00 PM ETCompany ParticipantsGraham Stanley - Vice President, Investor Relations and Strategic…


Source:Seeking Alpha
Dow Gains 1%; Tabula Rasa HealthCare Shares Spike Higher
Aug 07, 2023 18:30pm

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 350 points on Monday. The Dow traded up 1.02% to 35,423.19 while the NASDAQ rose 0.24% to 13,942.57. The S&P 500, also rose, gaining, 0.65% to 4,507.13. Check This Out: Merck, Delta Air Lines And 2 Other Stocks Insiders Are Selling Leading and Lagging Sectors Financials shares jumped by 1.4% on Monday. In trading on Monday, information technology shares fell 0.1%. Top Headline Henry Schein Inc (NASDAQ: HSIC ) reported better-than-expected second-quarter earnings. Henry Schein posted quarterly sales of $3.10 billion, slightly missing the consensus of $3.11 billion, up 2.3% Y/Y, including 0.2% decrease in local currencies excluding acquisitions, 2.9% growth from acquisitions, and a 0.4% decrease related to foreign currency exchange. Adjusted EPS of $1.31, up 0.8%, beat the estimate of $1.25. Equities Trading UP Vistagen Therapeutics, Inc. (NASDAQ: VTGN ) shares shot up 1,026% to $18.91 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of fasedienol met the primary and secondary endpoints.


Source:Benzinga